随着Summit公布首个海外三期的时间愈发临近,PD-(L)1/VEGF双抗的催化正在变得密集。近期三生制药的SSGJ-707划破沉寂,宣布了其国内二期潜在Me better数据,创新药投资者2025年值得期待的PD-(L)1/VEGF赛道的里程碑或事件又多了一个,那便是SSGJ-707何时拿下一个大Deal。01三生制药的me betterSSGJ-707,这个名字可能在今年之前都没有太引起...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.